Loading stock data…
DHR
$180.10-0.69 (-0.38%)
Market ClosedLast close Jun 12
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Danaher Corporation in the Healthcare sector is trading at $180.10 with a market capitalization of $121.7B. Wall Street consensus targets $242.35 (23 analysts), implying a +34.6% move over the next 12 months. The stock is currently 26% below its 52-week high of $242.80, remaining 11.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +34.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.95B↓ | $6.84B↑ | $6.05B↑ | $5.94B↑ | $5.74B |
| Gross Profit | $3.59B↓ | $3.97B↑ | $3.52B | $3.52B↑ | $3.51B |
| Operating Income | $1.34B↓ | $1.50B↑ | $1.15B↑ | $760.00M↓ | $1.27B |
| Net Income | $1.03B↓ | $1.20B↑ | $908.00M↑ | $555.00M↓ | $954.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$121.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.33
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.76%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.97%
Volume
Today's trading volume
2.04M
Recent News
Danaher Deepens Diagnostics Reach As Masimo Deal Reshapes Healthcare Focus
Danaher (NYSE:DHR) has completed its acquisition of Masimo. The deal adds Masimo's sensor technologies and AI-focused patient monitoring tools to Danaher's diagnostics portfolio. The combined business is positioned to offer a broader range of healthcare technology solutions across hospitals and clinics. For you as an investor, this move deepens NYSE:DHR's position in diagnostics and patient monitoring, areas where healthcare providers are increasingly focused on data quality and workflow...
3 Reasons to Avoid DHR and 1 Stock to Buy Instead
Danaher has gotten torched over the last six months - since December 2025, its stock price has dropped 21.2% to $178.42 per share. This may have investors wondering how to approach the situation.
Danaher Boosts Product Portfolio With the Acquisition of Masimo
DHR closes its $9.9B Masimo acquisition, adding AI-enabled patient-monitoring and sensor technologies to expand diagnostics solutions.
Implied Volatility Surging for Danaher Stock Options
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
1 Unstoppable Healthcare Cash Cow to Buy Hand Over Fist and Hold for 25 Years
Danaher (NYSE:DHR) is a stock built to own for 25 years because it supplies the irreplaceable plumbing of modern biologic drug manufacturing, and that position compounds quietly through every market cycle. The retirement-focused investor in their 50s or 60s wants a business with predictable cash flows, regulated switching costs, and a management system that turns ... 1 Unstoppable Healthcare Cash Cow to Buy Hand Over Fist and Hold for 25 Years